Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.

BACKGROUND Controversy exists regarding the risk of cardiovascular disease (CVD) associated with androgen deprivation therapy (ADT) in patients with prostate cancer. We sought to evaluate the association between gonadotropin-releasing hormone (GnRH) agonists versus GnRH antagonist and the risk of CVD in patients with prostate cancer with or without prior CVD. PATIENTS AND METHODS Using administrative databases from Quebec, Canada, we identified first-time GnRH agonists and antagonist (degarelix) users between January 2012 and June 2016. Follow-up ended at the earliest of the following: first CVD event (myocardial infarction [MI], stroke, ischemic heart disease [IHD], arrhythmia, and heart failure [HF]); switch of GnRH group; death; or December 31, 2016. Inverse probability of treatment weighting (IPTW) based on the propensity score was used to control for potential confounding. IPTW-Cox proportional hazards model accounting for competing risks was used to evaluate the association of interest. RESULTS Among 10,785 patients identified, 10,201 and 584 were on GnRH agonists and antagonist, respectively. Median age was 75 years (interquartile range, 69-81 years) for both groups. A total of 4,152 (40.7%) men in the GnRH agonists group and 281 (48.1%) men in the GnRH antagonist group had CVD in the 3-year period prior to ADT initiation. Risk of HF was decreased in the antagonist group compared with the GnRH agonist group among patients with prior CVD (hazard ratio [HR], 0.46; 95% CI, 0.26-0.79). Risk of IHD was decreased in the antagonist group in patients without prior CVD (HR, 0.26; 95% CI, 0.11-0.65). Use of antagonist was associated with an increased risk of arrhythmia among patients with no prior CVD (HR, 2.34; 95% CI, 1.63-3.36). CONCLUSIONS Compared with GnRH agonists, the GnRH antagonist was found to be associated with a decreased risk of HF, specifically among patients with prior CVD. Among those with no prior CVD, the GnRH antagonist was associated with a decreased risk of IHD but an increased risk of arrhythmia.

[1]  Deepak L. Bhatt,et al.  Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer , 2021, Circulation.

[2]  V. Jinga,et al.  Subclinical left ventricular dysfunction in men under androgen deprivation therapy for prostate cancer, revealed by speckle‐tracking‐derived parameters, repolarization, and myocardial injury markers , 2021, Echocardiography.

[3]  E. Oger,et al.  Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases , 2020, International journal of cancer.

[4]  M. Kirby,et al.  Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice , 2020, World Journal of Urology.

[5]  F. Saad,et al.  Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. , 2020, The New England journal of medicine.

[6]  M. Oderda,et al.  Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis , 2020, Therapeutics and clinical risk management.

[7]  M. Roe,et al.  Androgen deprivation therapy and cardiovascular disease. , 2020, Urologic oncology.

[8]  J. Beckman,et al.  Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[9]  D. Roden,et al.  Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes. , 2019, Circulation.

[10]  G. Witberg,et al.  Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease. , 2019, The Journal of urology.

[11]  C. Funck-Brentano,et al.  Cardiac arrhythmia considerations of hormone cancer therapies , 2019, Cardiovascular research.

[12]  P. Austin,et al.  Propensity‐score matching with competing risks in survival analysis , 2018, Statistics in medicine.

[13]  D. Roden,et al.  Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. , 2018, Circulation.

[14]  P. Kantoff,et al.  Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer , 2018, Journal of the Endocrine Society.

[15]  N. Keating,et al.  Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study , 2017, British Journal of Cancer.

[16]  Mark S. Litwin,et al.  The Diagnosis and Treatment of Prostate Cancer: A Review , 2017, JAMA.

[17]  C. Leclercq,et al.  Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data. , 2017, European journal of cancer.

[18]  H. Scher,et al.  Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE−/− mice , 2016, Scientific Reports.

[19]  I. Davis,et al.  ‘First, do no harm’: managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer , 2016, Internal medicine journal.

[20]  M. Mason,et al.  Cardiovascular effects of hormone therapy for prostate cancer. , 2015, Drug, healthcare and patient safety.

[21]  A. D'Amico,et al.  Adverse effects of androgen deprivation therapy and strategies to mitigate them. , 2015, European urology.

[22]  E. Adashi,et al.  FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca2+/CREB pathway , 2015, Aging cell.

[23]  L. Klotz,et al.  GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. , 2014, Urologic oncology.

[24]  B. Tombal,et al.  Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. , 2014, European urology.

[25]  P. Austin.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[26]  R. Kloner,et al.  Testosterone and the Cardiovascular System: A Comprehensive Review of the Basic Science Literature , 2013, Journal of the American Heart Association.

[27]  L. Tankó,et al.  Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. , 2011, The Journal of urology.

[28]  R. Cote,et al.  Impact of Adherence to Antihypertensive Agents on Clinical Outcomes and Hospitalization Costs , 2010, Medical care.

[29]  Peter C Austin,et al.  The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies , 2010, Statistics in medicine.

[30]  Peter C. Austin,et al.  The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational Studies , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[32]  Peter C Austin,et al.  The performance of different propensity score methods for estimating marginal hazard ratios , 2007, Statistics in medicine.

[33]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .